MEDEZE Pushes Innovation and Sustainability, Securing THB54 Million Net Profit in 2Q25

Medeze Group Public Company Limited (SET: MEDEZE) has announced 2Q25 consolidated financial statement through the Stock Exchange of Thailand as follows:

 

MEDEZE reported a net profit of 54.78 million baht in the second quarter of 2025, representing a decrease of 37% from the same quarter last year. The decline was primarily due to two factors: 1) Revenue did not grow as planned; and 2) Increased expenses in 2025, including: 1) Personnel costs due to hiring more employees for the medical laboratory, sales and marketing, and management departments; 2) Higher depreciation and amortization expenses resulting from new asset investments made to support business expansion, such as the new sales and marketing building, a new warehouse, and a solar cell power system; and 3) Public relations expenses for the ATMPs Sandbox project. The project is considered a significant step forward for the Group and is beneficial to Thailand, as it aims to provide knowledge and understanding to both customers and the general public.

Total revenue was at 197.64 million baht, which was a decrease of 11% from the same quarter last year. The decline was primarily due to the Tariff Effect, an economic impact that affected producers, consumers, and the overall market both domestically and internationally. This was compounded by a decrease in foreign customers, particularly from Cambodia, as well as the earthquake event in the first quarter of 2025. These factors resulted in the Group’s total revenue in the first half of 2025 not growing as planned. However, when compared to the first half of the previous year, the Group was still able to maintain its total revenue at the same level.

MEDEZE and its subsidiaries are engaged in the business of analyzing, sorting, culturing and storing stem cells and testing the potential of immune cells. The Group has been in business for more than 14 years, providing services covering long-term stem cell storage through innovation and modern technology, with the Association for the Advancement of Blood and Biotherapies (AABB) from the United States, to having a Class 100 cleanroom aseptic laboratory with modern equipment and technology in the stem cell banking industry, such as freezing systems in liquid nitrogen tanks. AutoXpress and Quantum-type mesenchymal stem cell multiplication culture, etc. The Group will focus on using more automated innovations in the Group’s operational processes to maximize efficiency and effectiveness, to ensure the safety of stem cell storage.

The Group formulated an organizational sustainability management policy to be implemented, including: 1) Adhere to business operations with fairness and transparency in accordance with the principles of good corporate governance; 2) Focus on the directors executives, employees, and employees at all levels to promote and operate in accordance with the Sustainable Development Policy; 3) Raise awareness and responsibility for sustainable development approaches; and 4) Commit to developing personnel and applying knowledge and expertise in analysis, sorting, culturing and depositing stem cells and checking the potential of immune cells to participate in improving the quality of life in a sustainable manner.

Additionally, the company recognizes the importance of sustainable business growth under Corporate Social Responsibilities by focusing on business operations with care and care for stakeholders. Economic, social and environmental values with morality, ethics and ethics, which will bring benefits to the community along with the growth of the company at the same time.